Required Immunizations for Carroll College
Carroll College requires that you provide proof of the following immunization prior to registration:
- MMR (Measles, Mumps, Rubella): proof of two MMRs are required
DPT (Diphtheria, Pertuissis, Tetanus) A minimum of three shots, last one within ten years or a booster within ten years
TD (Tetanus Booster) One shot required to be within the past ten years
Polio Series (OPV or IPV) a minimum of three doses
Tuberculosis (Tb or PPD) skin test - required within one year prior to enrollment
Meningitis - All new students are required to provide proof of having received a meningitis vaccination.
Meningococcal Vaccine
Menactra - the 1st conjugate quadrivalent meningococcal vaccine. Now licensed and available for use in the United States, Menactra vaccine offers the following benefits:
Recommended by the ACIP (Advisory Committee on Immunization Practices)
Menactra is now recommended for:
* Young adolescents (11 - 12-year-olds)
* Teens entering high school or
* College freshmen living in dormitories
Demonstrated response following a single intramuscular injection
* Menactra vaccine produces antibody responses that are equivalent to the currently licensed meningococcal polysaccharide vaccine
* 82% to 97% of adolescents achieved a >4-fold rise in antibody titers following administrationof Menactra vaccine.
* Among seronegative adolescents, 98% to 100% achieved a > 4-fold rise in antibody titers following administration of Menactra vaccine.
Demonstrated safety
* Local reactions with Menactra vaccine are very similar to those following tetanus and diphtheria (Td)
* The majority of adverse reactions were reported as mild and consisted mainly of pain, redness, and induration at the injection site, headache, fatigue and malaise
* Can be administered at the same time as the adolescent Td booster
The ACIP decision to recommend immunization with Menactra (meningococcal) is especially important in light of recent data from the Centers for Disease Control and Prevention (CDC) that indicate meningococcal disease rates begin to rise during adolescence and peak between the ages of 15 and 24 years. Case fatality rates are up to 5 times higher among adolescents and young adults (15 to 24 years old) compared with younger populations.
There are risks associated with all vaccines. Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine or to latex, which is used in the vial stopper. Menactra vaccine should not be given to persons with any bleeding disorder, such as hemophilia or thrombocytopenia, or to persons on anticoagulant therapy unless the potential benefit clearly outweighs the risk of administration.
Remember, meningococcal disease develops rapidly, and vaccination is the best protection.